CRISPR Therapeutics (NASDAQ:CRSP) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report issued on Tuesday,Benzinga reports. They currently have a $84.00 price target on the stock.

CRSP has been the topic of a number of other research reports. Barclays cut their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. JMP Securities reiterated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, December 20th. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Chardan Capital reissued a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $78.38.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $38.36 on Tuesday. The stock has a market capitalization of $3.27 billion, a P/E ratio of -13.55 and a beta of 1.62. CRISPR Therapeutics has a 1 year low of $36.52 and a 1 year high of $91.10. The company’s 50-day moving average is $45.70 and its 200 day moving average is $48.37.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the prior year, the company earned ($1.41) earnings per share. Research analysts anticipate that CRISPR Therapeutics will post -5.13 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the transaction, the chief executive officer now owns 196,540 shares in the company, valued at $10,931,554.80. This trade represents a 13.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Mirador Capital Partners LP purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth $297,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of CRISPR Therapeutics by 9.2% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 44,305 shares of the company’s stock worth $1,744,000 after acquiring an additional 3,737 shares during the last quarter. 180 Wealth Advisors LLC boosted its stake in shares of CRISPR Therapeutics by 18.4% during the 4th quarter. 180 Wealth Advisors LLC now owns 5,167 shares of the company’s stock worth $203,000 after acquiring an additional 803 shares during the last quarter. AdvisorNet Financial Inc lifted its stake in shares of CRISPR Therapeutics by 91.1% during the 4th quarter. AdvisorNet Financial Inc now owns 2,478 shares of the company’s stock valued at $98,000 after buying an additional 1,181 shares in the last quarter. Finally, Green Alpha Advisors LLC lifted its stake in shares of CRISPR Therapeutics by 28.6% during the 4th quarter. Green Alpha Advisors LLC now owns 24,629 shares of the company’s stock valued at $969,000 after buying an additional 5,471 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.